Survivorship after neoadjuvant chemotherapy - Authors' reply
Lancet Oncol
.
2022 Mar;23(3):e96.
doi: 10.1016/S1470-2045(22)00085-7.
Authors
Christina Yau
1
,
Marie Osdoit
2
,
Laura J Esserman
3
,
W Fraser Symmans
4
Affiliations
1
Department of Surgery, University of California, San Francisco, CA 94158, USA. Electronic address: hoisze.yau@ucsf.edu.
2
Department of Surgery, Institut Curie, Paris, France.
3
Department of Surgery, University of California, San Francisco, CA 94158, USA.
4
Department of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
PMID:
35240097
DOI:
10.1016/S1470-2045(22)00085-7
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Humans
Neoadjuvant Therapy* / adverse effects
Survivorship*